Adverse Events Associated with Risperidone Use in Pediatric Patients: A Retrospective Biobank Study

Abstract Background Although risperidone is increasingly used for behavioral indications in children, the associated adverse events (AEs) are not well defined in this population. Objective We determined the incidence of and risk factors for AEs among children treated with risperidone at our institut...

Full description

Saved in:
Bibliographic Details
Main Authors: Kazeem A. Oshikoya (Author), Robert Carroll (Author), Ida Aka (Author), Dan M. Roden (Author), Sara L. Van Driest (Author)
Format: Book
Published: Adis, Springer Healthcare, 2019-03-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_31832421b38d45eebb7f9f0b29c743c3
042 |a dc 
100 1 0 |a Kazeem A. Oshikoya  |e author 
700 1 0 |a Robert Carroll  |e author 
700 1 0 |a Ida Aka  |e author 
700 1 0 |a Dan M. Roden  |e author 
700 1 0 |a Sara L. Van Driest  |e author 
245 0 0 |a Adverse Events Associated with Risperidone Use in Pediatric Patients: A Retrospective Biobank Study 
260 |b Adis, Springer Healthcare,   |c 2019-03-01T00:00:00Z. 
500 |a 10.1007/s40801-019-0151-7 
500 |a 2199-1154 
500 |a 2198-9788 
520 |a Abstract Background Although risperidone is increasingly used for behavioral indications in children, the associated adverse events (AEs) are not well defined in this population. Objective We determined the incidence of and risk factors for AEs among children treated with risperidone at our institution, an academic medical center with inpatient, outpatient, generalist, and specialist pediatric care. Methods The study included children aged ≤ 18 years with ≥ 4 weeks of risperidone exposure. Data were obtained using de-identified electronic health records. AEs were defined as any untoward event attributed to risperidone reported by the patient, parent/guardian, or physician or detected following a laboratory investigation. Associations between AEs and clinical variables were determined using univariate and multivariate analyses. Results The study cohort included 371 individuals (median age 7.8 years [interquartile range 5.9-10.2]; 271 [73.0%] male). The two most common primary diagnoses were attention-deficit/hyperactivity disorder (160 [43.1%]) and autism (102 [27.5%]). The most frequent indications for risperidone were aggression (166 [44.7%]) and behavioral problems (114 [30.7%]). Altogether, 110 (29.6%) individuals had 156 AEs. Weight gain (32 [20.5%]) and extrapyramidal symptoms (23 [14.7%]) were the most common AEs. Aggression, irritability, and self-injurious behavior were positively associated with AEs, and concomitant analgesics and antibiotics were negatively associated. In multivariate analysis, associations remained significant for self-injurious behavior (adjusted odds ratio [aOR] 3.1; 95% confidence interval [CI] 1.7-5.4) and concomitant antibiotics (aOR 0.2; 95% CI 0.1-0.9). Conclusions Nearly one in three children treated with risperidone for ≥ 1 month experienced one or more AEs. Particular vigilance is warranted for children with self-injurious behavior. 
546 |a EN 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Drugs - Real World Outcomes, Vol 6, Iss 2, Pp 59-71 (2019) 
787 0 |n http://link.springer.com/article/10.1007/s40801-019-0151-7 
787 0 |n https://doaj.org/toc/2199-1154 
787 0 |n https://doaj.org/toc/2198-9788 
856 4 1 |u https://doaj.org/article/31832421b38d45eebb7f9f0b29c743c3  |z Connect to this object online.